Literature DB >> 11110504

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.

E Mannucci1, A Ognibene, F Cremasco, G Bardini, A Mencucci, E Pierazzuoli, S Ciani, A Fanelli, G Messeri, C M Rotella.   

Abstract

AIMS: To assess differences in circulating leptin and glucagon-like peptide (GLP)-1 concentrations before and after an oral glucose load, in euglycaemic and isoinsulinaemic conditions, between obese patients with and without Type 2 diabetes mellitus.
METHODS: Ten male obese (body mass index (BMI) > 30 kg/m2) patients with Type 2 diabetes and 20 matched non-diabetic subjects were studied. Leptin, GLP-1(7-36)amide and GLP-1(7-37) concentrations were measured 0, 30, 60, and 90 min after a 50-g oral glucose load administered 90 min after the beginning of a euglycaemic hyperinsulinaemic clamp.
RESULTS: GLP-1(7-36)amide concentrations before the glucose load were significantly lower in diabetic patients than in controls (median (quartiles): 50.5 (44.7-53.2) vs. 128.7(100-172.5) pg/ml; P < 0.01), while no difference was observed in baseline GLP-1(7-37). In non-diabetic subjects, GLP-1(7-36)amide and GLP-1(7-37) concentrations increased significantly after the oral glucose load, while no glucose-induced increase in GLP-1 concentration was observed in diabetic patients. GLP-1(7-36)amide at 30, 60, and 90 min, and GLP-1(7-37) at 30 min, of the glucose challenge, were significantly lower in diabetic patients. Leptin concentrations were not significantly different in diabetic patients when compared to non-diabetic subjects, and they did not change after the oral glucose load. DISCUSSION: Leptin concentrations are not significantly modified in obese Type 2 diabetic patients. GLP-1(7-36)amide baseline concentrations are reduced in Type 2 diabetes; moreover, diabetic subjects show an impaired response of GLP-1 to oral glucose in euglycaemic, isoinsulinaemic conditions. This impairment, which is not the result of differences in glycaemia or insulinaemia during assessment, could contribute to the pathogenesis of hyperglycaemia in Type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110504     DOI: 10.1046/j.1464-5491.2000.00367.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  29 in total

1.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Alberto Patriti; Enrico Facchiano; Annibale Donini
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

2.  Insulin-regulated glucagon-like peptide-1 release from L cells: actin' out.

Authors:  Debbie C Thurmond
Journal:  Endocrinology       Date:  2009-12       Impact factor: 4.736

Review 3.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

Review 4.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

Review 5.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

6.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

Review 7.  Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes?

Authors:  Milagros Gloria Huerta
Journal:  Rev Endocr Metab Disord       Date:  2006-09       Impact factor: 6.514

8.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

9.  Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.

Authors:  Gareth E Lim; Guan J Huang; Nina Flora; Derek LeRoith; Christopher J Rhodes; Patricia L Brubaker
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

10.  Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients.

Authors:  E Mannucci; L Pala; M Monami; L Da Vico; G Bardini; I Dicembrini; S Ciani; C Lamanna; N Marchionni; C M Rotella
Journal:  J Endocrinol Invest       Date:  2009-09-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.